Feasibility and reliability of health-related quality of life measurements among tuberculosis patients

Quality of Life Research

Volumn 13, Issue 3, 2004, Pages 653-665

  Dion, M J ^a,b   Tousignant, P ^a,c   Bourbeau, J ^a,b   Menzies, D ^a,b   Schwartzman, K ^a,b,d  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c Gouvernement du Quebec   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Feasibility; Isoniazid; Latent Tuberculosis; Quality of life; Questionnaires; Reliability; Tuberculosis

Indexed keywords

CONFERENCE PAPER; CORRELATION COEFFICIENT; DRUG SELF ADMINISTRATION; FEASIBILITY STUDY; HEALTH CARE; HEALTH STATUS; HUMAN; INTERVIEW; MEASUREMENT; MENTAL CAPACITY; MORTALITY; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; QUESTIONNAIRE; RELIABILITY; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; EMIGRATION AND IMMIGRATION; FEMALE; HEALTH STATUS; HUMANS; ISONIAZID; MALE; PSYCHOMETRICS; QUALITY OF LIFE; QUEBEC; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 1942486753     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:QURE.0000021320.89524.64     Document Type: Conference Paper

References (44)

1. World Health Organisation. Global Tuberculosis Control. WHO Report 2001. Geneva: WHO, 2001.
2. Njoo H, Nault P, Phypers M. Tuberculosis in Canada, 1998. Ottawa: Health Canada, 2001.
3. Fitzgerald JM, Gafni A. A cost-effectiveness analysis of the routine use of isoniazid prophylaxis in patients with a positive Mantoux skin test. Am Rev Respir Dis 1990; 142(4): 848-853.
4. Salpeter SR, Sanders GD, Salpeter EE, Owens DK. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: A risk-benefit and cost-effectiveness analysis. Ann Intern Med 1997; 127(12): 1051-1061.
5. Tsevat J, Taylor WC, Wong JB, Pauker SG. Isoniazid for the tuberculin reactor: Take it or leave it. Am Rev Respir Dis 1988; 137(1): 215-220.
6. Geiter L (ed.), for the Committee on the Elimination of Tuberculosis in the United States. Ending Neglect: The Elimination of Tuberculosis in the United States. Washington: Washington National Press Academy, 2000.
7. American Thoracic Society and the Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Cri Care Med 2000; 161(4): S222-S247.
8. Canadian Lung Association/Health Canada. In: Long R (ed.), Canadian Tuberculosis Standards, 5th ed. Ottawa: Canadian Lung Association, 2000.
9. Schwartzman K, Menzies D. Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis. Am J Respir Crit Care Med 2000; 161: 780-789.
10. Dasgupta K, Schwartzman K, Marchand R, Tannenbaum T, Brassard P, Menzies D. Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born population. Am J Respir Crit Care Med 2000; 162: 2079-2086.
11. Sumartojo E. When tuberculosis treatment fails. A social behavioral account of patient adherence. Am Rev Respir Dis 1993; 147: 1311-1320.
12. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston: Medical Outcomes Trust, 1993.
13. Ware JEJ, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scale: A User's Manual. 5th ed. Boston: Medical Outcome Trust, 1994.
14. Wood-Dauphinee S, Gauthier L, Gandek B, Magnan L, Pierre U. Readying a US measure of health status, the SF-36, for use in Canada. Clin Invest Med 1997; 20(4): 224-238.
15. EuroQol group. A new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
16. Brooks R. EuroQol: The current state of play. Health Policy 1996; 37: 53-72.
17. Mayo NE, Goldberg M, Kind P. Calibrating the ED-5D for a Canadian population. Proceedings from EuroQol Plenary Meeting Rotterdam 1997. Rotterdam: Center for Health Policy and Law, Erasmus University, 1998; 25-40.
18. Dion M, Tousignant P, Bourbeau J, Menzies D, Schwartzman K. Measurement of health preferences among patients with tuberculous infection and disease. Med Decision Making 2002 22[Suppl]: S102-S114.
19. Rosner B. Fundamentals of Biostatistics. 3rd ed. Belmont: Duxbury Press, 1990.
20. Drummond MF, O'Brien B, Stoddart G, Torrance G. Methods for the economic evaluation of health care programmes. 2nd ed. Toronto: Oxford Medical Publications, 1997.
21. Streiner DL, Norman GR. Health Measurement Scales. A Practical Guide to Their Developement and Use. 2nd ed. New York: Oxford medical publications, 1995.
22. Kramer MS, Feinstein AR. Clinical biostatistics LIV. The biostatistics of concordance. Clin Pharmacol Ther 1981; 29(1): 111-123.
23. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33(1): 159-174.
24. Stata Statistical Software: Release 6.0 [computer program]. Stata Corporation. College Station, Texas: Stata Corporation, 1999.
25. Donner A, Eliasziw M. Sample size requirements for reliability studies. Stat Med 1987; 6(4): 441-448.
26. Bouchet C, Guillemin F, Paul-Dauphin A, Briancon S. Selection of quality-of-life measures for a prevention trial: A psychometric analysis. Cont Clin Trials 2000; 21(1): 30-43.
27. Dorman PJ, Slattery J, Farrell B, Dennis MS, Sandercock, PA. A randomised comparison of the EuroQol and Short Form-36 after stroke. Br Med J 1997; 315(7106): 461.
28. Rivest P, Tannenbaum T, Bedard L. Epidemiology of tuberculosis in Montreal. CMAJ 1998; 158(5): 605-609.
29. Jenkins CD. Assessment of outcomes of health intervention. Soc Sci Med 1992; 35(4): 367-375.
30. Vissandjee B, Dupere S. Culture, migration et instrument de mesure: défís incontournables. J Int Migrat Integrat 2001; 1(4): 477-492.
31. Wagner AK, Gandek B, Aaronson NK, et al. Cross-cultural comparisons of the content of SF-36 translations across 10 countries: Results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998; 51(11): 925-932.
32. Chang DF, Chun CA, Takeuchi DT, Shen H. SF-36 health survey: tests of data quality, scaling assumptions, and reliability in a community sample of Chinese Americans. Med Care 2000; 38(5): 542-548.
33. Chie WC, Huang CS, Chen JH, Chang KJ. Measurement of the quality of life during different clinical phases of breast cancer. J Formosan Med Assoc 1999; 98(4): 254-260.
34. Arocho R, McMillan CA, Sutton-Wallace P. Construct validation of the USA-Spanish version of the SF-36 health survey in a Cuban-American population with benign prostatic hyperplasia. Qual Life Res 1998; 7(2): 121-126.
35. Thumboo J, Fong KY, Ng TP, et al. Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore. J Rheumatol 1999; 26(1): 97-102.
36. Hopman WM, Towheed T, Anastassiades T, et al. Canadian normative data for the SF-36 health survey. CMAJ 2000; 163(3): 265-271.
37. Beaton DE, Hogg-Johnson S, Bombardier C. Evaluating changes in health status: Reliability and responsiveness of five generic health status measures in workers with musculoskeletal disorders. J Clin Epidemiol 1997; 50(1): 79-93.
38. Fransen M, Edmonds J. Reliability and validity of the EuroQol in patients with osteoarthritis of the knee. Rheumatology (Oxford) 1999; 38(9): 807-813.
39. Dorman P, Slattery J, Farrell B, Dennis M, Sandercock P. Qualitative comparison of the reliability of health status assessments with the EuroQol and SF-36 questionnaires after stroke. United Kingdom Collaborators in the International Stroke Trial. Stroke 1998; 29(1): 63-68.
40. American Thoracic Society and the Centers for Disease Control and Prevention. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
41. Dorman PJ, Dennis M, Sandercock P. How do scores on the EuroQol relate to scores on the SF-36 after stroke? Stroke 1999; 30(10): 2146-2151.
42. Myers C, Wilks D. Comparison of Euroqol EQ-5D and SF-36 in patients with chronic fatigue syndrome. Qual Life Res 1999; 8(1-2): 9-16.
43. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998; 316: 736-741.
44. Tuberculosis Trials Consortium. The Tuberculosis Trials Consortium: A model for clinical trials collaborations. Public Health Reports 2001; 116[Suppl 1]: 41-49.